ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)

Cover Page

Cite item

Full Text

Abstract

The article provides an overview of the efficacy and tolerability of one of the representatives of the class angiotensin receptor blockers II - olmesartan medoxomil (Kardosal). Analyzed are the characteristics and pharmacological activity of olmesartan medoxomil antihypertensive monotherapy, in combination with other antihypertensive drugs, in different groups of patients. The article describes the renal protective properties of the drug, its safety profile. It also discusses the reasons for poor adherence therapy in patients with arterial hypertension.

About the authors

M. G Bubnova

State Research Center of Preventive Medicine Russia, Moscow

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лабораторией профилактики атеросклероза и тромбоза

References

  1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the on management of arterial hypertension. Eur Heart J 2013. doi: 10.1093/eurheartj/eht151.
  2. James P.A, Oparil S, Carter B.L et al. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014. doi: 10.1001/jama.2013.284427.
  3. Mancini G.B.J, Etminan M, Zhang B et al. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. JACC 2006; 47 (12): 2554-60.
  4. Ferrario C.M, Strawn W.B. Role of the renin - angiotensin - aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 2006; 98 (1): 121-8.
  5. Jacoby D.S, Rader D.J. Renin - angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003; 163 (10): 1155-64.
  6. Dzau V. The cardiovascular continuum and renin - angiotensin - aldosterone system blockade. J Hypertens 2005; 23 (Suppl. 1): S9-17.
  7. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21 (1): 20-7.
  8. Touyz R.M. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90 (4): 449-55.
  9. Papademetriou V. Inhibition of the renin - angiotensin - aldosterone system to prevent ischemic and atherothrombotic events. Am Heart J 2009; 157 (6 Suppl. 1): S25-30.
  10. Turnbull F. Effects of different blood - pressure - lowering regimens on major cardiovascular events: results of prospectively - designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
  11. Carey R.M, Wang Z.Q, Sigary H.M. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000; 35: 155-63.
  12. Scott L.J, McCormack P.L. Olmesartan: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72.
  13. Mire D.E, Silfani T.N, Pugsley M.K. A Review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585-93.
  14. Mizuno M, Sada T, Ikeda M et al. Pharmacology of CS0866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181-8.
  15. Warne G.T, Jarvis B. Olmesartan medoxomil. Drugs 2002; 62: 1345-53.
  16. Agata J, Ura N, Yoshida H et al. Олмесартан - блокатор рецепторов к ангиотензину II, обладающий ингибиторным эффектом на ангиотензинпревращающий фермент. Hypertens Res 2006; 29 (11): 865-74.
  17. Brunner H.R, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001; 19 (S1): S15-S20.
  18. Giles T.D, Robinson T.D. Effects of Olmesartan Medoxomil on Systolic Blood Pressure and Pulse Pressure in the Management of Hypertension. Am J Hypertens 2004;17: 690-5.
  19. Ichikawa S, Takayama Y. Long - term effects of Olmesartan, an Ang II receptor antagonist, on blood pressure and the renin - angiotensin - aldosterone system in hypertensive patients. Hypertens Res 2001; 24 (4): 641-6.
  20. Oparil S, Williams D, Chrysant S.G et al. Comparative efficacy of Olmesartan, losartan, valsartan and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3 (5): 283-92.
  21. Brunner H.R, Stumpe K.O, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23 (7): 419-30.
  22. Scott L.J, McCormack P.L. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72.
  23. Heagerty A.M, Mallion J.M. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension: efficacy and safety data from clinical trials. Drugs Aging 2009; 26: 61-76.
  24. Mallion J.M, Heagerty A, Laeis P. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension. J Hypertens 2007; 25: 2168-77.
  25. Малакко Э., Омбони С., Вульпе М. и др. Антигипертензивная эффективность и безопасность олмесартана медоксомила и рамиприла у пожилых пациентов с мягкой и умеренной эссенциальной гипертензией: результаты исследования ESPORT. Рос. кардиол. журн. 2012; 1 (93): 8-18.
  26. Nakayama S, Watada H, Mita T et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early - stage type-2 diabetics with hypertension. Hypertens Res 2008; 31 (1): 7-13.
  27. Menne J, Jr Izzo J.L, Ito S et al. For the ROADMAP investigators. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens 2012, 30: 811-8.
  28. Yanagi M, Tamura K, Fujikawa T et al. The ahgionetsin II type 1 receptor bloker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease. Hypertens Res 2012; 15.doi: 10.1038/hr.2012.184.
  29. Hermida R.C, Ayala D.E, Mojon A, Fernandez J.R. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol 2011; 22: 2313-21.
  30. Chrysant S.G et al. Evaluation of antihypertensive therapy with the combination of Olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17 (3): 252-9.
  31. Rump L.C, Ambrosioni E. Initial combination therapy with Olmesartan/hydrochlorothiazide shows superior blood pressure control rate in moderate to severe. Hypertension ESC/ESH 14th Annual Meeting, Paris, 2004.
  32. Ram C.V. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial - design studies. J Clin Hypertens 2004; 6 (10): 569-77.
  33. Palatini P. Combination Therapy in the Management of Hypertension: Focus on Angiotensin Receptor Blockers Combined With Diuretics. J Clin Hypertens 2005; 7 (2): 96-101.
  34. Chrysant S.G, Melino M, Karki S et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double - blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther 2008; 30: 587-604.
  35. Klag M.J, Whelton P.K, Randall B.L et al. Blood pressure and end - stage renal disease in men. N Engl J Med 1996; 334: 13-8.
  36. Koc Y, Mazi E, Sakaci T. Effect of olmesartan on cystain C level in the patients with essential hypertension. Eur Rev Med Pharmacol Sci 2011; 55 (12): 1388-94.
  37. Fliser D, Wagner K, Loss A et al. Chronic angiotensin II receptor blokade reduces (itra) renal vascular resistence in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16 (4): 1135-40.
  38. Ikeda H, Hamamoto Y, Honjo S et al. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes. Diabetes Res Clin Pract 2009; 83 (1): 117-8.
  39. Rodrìguez-Iturbe B, Sato T, Quiroz Y. AT1-receptor blockade prevents proteinuria, renal failure, hyperlipidemia and glomerulosclerosis in the Imai rat. Kidney Int 2004; 66: 668-75.
  40. Yoshida K, Xu H.L, Kawamura T et al. Chronic Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism in Rats With Chronic Renal Failure. J Cardiovasc Pharmacol 2002; 40: 533-42.
  41. Koga K, Yamagishi S, Takeuchi M et al. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med 2002; 8 (10): 591-9.
  42. Püchler K, Laeis P, Stumpe K.O. Blood pressure response, but not adverse event Incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (S.1): S41-S48.
  43. Бубнова М.Г., Аронов Д.М.. Эффективность фиксированной комбинации лозартана и гидрохлоротиазида у больных артериальной гипертонией при разном типе ремоделирования левого желудочка в наблюдательной программе ПРОГНОЗ. CardioСоматика. 2012; 3: 32-41.
  44. Rumsfeld J.S, Masoudi F.A. Effect of Medication Nonadherence on Hospitalization and Mortality Among Patients With Diabetes Mellitus. Arch Intern Med 2006; 166: 1836-41.
  45. Breekveldt-Postma N.S, Siiskonen S.J, Penning - van Beest F.J.A, et al. Non - persistent use of antihypertensive drugs leads to increased risk of hospitalizations for acute myocardial infarction or stroke. Value Health 2006; 9: A339.
  46. Perreault S, Dragomir A, Roy L et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol 2010; 69: 74-84.
  47. Perreault S, Dragomir A, Roy L et al. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Intern Med 2009; 266: 207-18.
  48. Kettani F.Z, Dragomir A, Cote R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213-20.

Copyright (c) 2014 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies